Long-term Outcomes after the Discontinuation of Anti-Tumor Necrosis Factor-α Therapy in Patients with Inflammatory Bowel Disease under Clinical Remission: A Korean Association for the Study of Intestinal Disease Multicenter Study.
Sung Noh HongEun Ae KangSoo-Kyung ParkSung Noh HongYou Sun KimKi Bae BangKyeong Ok KimHong Sub LeeSang Bum KangSeung Yong ShinEun Mi SongJong-Pil ImChang Hwan Choinull nullPublished in: Gut and liver (2021)
More than 60% of IBD patients in remission under anti-TNF therapy relapsed within 5 years of treatment cessation. Anti-TNF re-induction was effective. However, half of the patients discontinued anti-TNF therapy, and 50% of these patients discontinued treatment owing to loss of response.
Keyphrases
- end stage renal disease
- rheumatoid arthritis
- chronic kidney disease
- ejection fraction
- newly diagnosed
- prognostic factors
- peritoneal dialysis
- patient reported outcomes
- patients with inflammatory bowel disease
- diffuse large b cell lymphoma
- patient reported
- combination therapy
- replacement therapy
- ulcerative colitis
- hodgkin lymphoma